Drug · DIN 02300699
ATRIPLA
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since December 22, 2021; first marketed October 23, 2007.
- Drug Identification Number (DIN)
- 02300699
- Company (DIN owner)
- Gilead Sciences, Inc.Foster City, California, United States
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Emtricitabine, tenofovir disoproxil and efavirenz J05AR06
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| EFAVIRENZ | 600 MG | |
| EMTRICITABINE | 200 MG | |
| TENOFOVIR DISOPROXIL FUMARATE | 300 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 20, 2018: NOC 20642New Drug Submission (NDS) · Manufacturer name change
- October 15, 2007: NOC 9091New Drug Submission (NDS)